ACE Technology Guidances communicate recommendations from the MOH Drug Advisory Committee or the MOH Medical Technology Advisory Committee on the funding status and appropriate use of drugs, vaccines or medical technologies that have been evaluated by ACE. The guidances also include the Committee’s rationale for the funding recommendations, and key clinical and economic evidence which informed their deliberations. Plain English Summaries (PES) to explain ACE Technology Guidances are available for patients and the public.

Published on 01 Sep 2023
Last Updated on 02 Jan 2024
A- A+
Guidance Recommendations
The Ministry of Health’s Drug Advisory Committee has recommended:
  • Olaparib 100 mg and 150 mg tablets as adjuvant treatment of patients with germline BRCA-mutated, HER2-negative, high-risk early breast cancer who have previously been treated with neoadjuvant or adjuvant chemotherapy. Maximum duration of treatment: 1 year.

Funding status

Olaparib 100 mg and 150 mg tablets are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication from 1 March 2024.

Clinical indication, subsidy class and MediShield Life claim limit for olaparib are provided in the Annex.

Olaparib for treating germline BRCA-mutated HER2-negative high-risk early breast cancer (Updated 2 Jan 2024) PES Olaparib for BRCA-mutated HER2-negative early breast cancer (Updated 2 Jan 2024)